AN2 Therapeutics Overview
- Year Founded
-
2017
- Status
-
Public
- Employees
-
21
- Stock Symbol
-
ANTX
- Share Price
-
$5.10
- (As of Friday Closing)
AN2 Therapeutics General Information
Description
AN2 Therapeutics Inc is a biopharmaceutical company focused on discovering and developing novel small molecule therapeutics derived from its boron chemistry platform. The company has a pipeline of boron-based compounds in development for Chagas disease, non-tuberculous mycobacterial (NTM) and melioidosis, along with early-stage programs focused on targets in infectious diseases and oncology. Product candidate AN2-502998 Epetraborole.
Contact Information
Website
www.an2therapeutics.comCorporate Office
- 1300 El Camino Real
- Suite 100
- Menlo Park, CA 94025
- United States
Corporate Office
- 1300 El Camino Real
- Suite 100
- Menlo Park, CA 94025
- United States
AN2 Therapeutics Stock Performance
As of 20-Nov-2026, AN2 Therapeutics’s stock price is $5.10. Its current market cap is $193M with 37.9M shares.
(As of Friday Closing)
| Stock Price | Previous Close | 52 wk Range | Market Cap | Shares | Average Volume | EPS |
|---|---|---|---|---|---|---|
| $5.10 | $5.22 | $1.00 - $7.19 | $193M | 37.9M | 288K | -$0.92 |
AN2 Therapeutics Financials Summary
As of 30-Sep-2026, AN2 Therapeutics has a trailing 12-month revenue of null.
|
In Thousands, USD |
TTM 30-Sep-2026 | FY 2025 31-Dec-2025 | FY 2024 31-Dec-2024 | FY 2023 31-Dec-2023 |
|---|---|---|---|---|
| EV | 122,370 | (30,683) | (52,193) | 485,584 |
| Revenue | 0 | 0 | 0 | 0 |
| EBITDA | (37,441) | (38,108) | (56,787) | (69,592) |
| Net Income | (34,880) | (35,174) | (51,321) | (64,732) |
| Total Assets | 81,955 | 61,950 | 92,087 | 138,744 |
| Total Debt | 0 | 0 | 0 | 0 |
AN2 Therapeutics Valuation & Funding
| Deal Type | Date | Amount | Valuation/ EBITDA |
Post-Val | Status | Debt |
|---|
AN2 Therapeutics Cap Table
| Stock | # of Shares Authorized |
Par Value | Dividend Rate (%) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price |
% Owned |
|---|
AN2 Therapeutics Comparisons
Industry
Financing
Details
AN2 Therapeutics Competitors (6)
One of AN2 Therapeutics’s 6 competitors is Spero Therapeutics, a Formerly VC-backed company based in Cambridge, MA.
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| Spero Therapeutics | Formerly VC-backed | Cambridge, MA | ||||
| Ambagon Therapeutics | Venture Capital-Backed | Eindhoven, Netherlands | ||||
| VLP Therapeutics | Venture Capital-Backed | Gaithersburg, MD | ||||
| RedHill Biopharma | Formerly VC-backed | Raleigh, NC | ||||
| BITT (Drug Discovery) | Venture Capital-Backed | Boston, MA |
AN2 Therapeutics Patents
AN2 Therapeutics Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| WO-2026236678-A1 | Boron heterocycle containing compounds as enpp inhibitors, and uses thereof | Pending | 09-May-2025 | ||
| WO-2026080526-A1 | Boron heterocycle containing compounds and uses thereof | Pending | 08-Oct-2024 | ||
| WO-2026060334-A1 | Boron heterocycle containing compounds as enpp inhibitors and uses thereof | Pending | 13-Sep-2024 | ||
| EP-4766704-A1 | Chemical compounds | Pending | 30-Jun-2023 | ||
| WO-2025007074-A9 | Chemical compounds | Inactive | 30-Jun-2023 | C07D405/04 |
AN2 Therapeutics Signals
AN2 Therapeutics Investors
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds | Contact Info |
|---|
AN2 Therapeutics ESG
Risk Overview
Risk Rating
Updated November, 04, 2026
34.65 | High Risk
Risk Scale
A lower score indicates better sustainability
Negl
0-10
Low
10-20
Med
20-30
High
30-40
Severe
40+
Exposure
Exposure refers to the extent to which a company is exposed to different material ESG issues
Management
Management is related to actions taken to manage ESG issues
Peers Analysis
Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.
Global
Covered Companies
of 13,592
Rank
Percentile
Pharmaceuticals
Industry
of 852
Rank
Percentile
Biotechnology
Subindustry
of 431
Rank
Percentile
AN2 Therapeutics FAQs
-
When was AN2 Therapeutics founded?
AN2 Therapeutics was founded in 2017.
-
Where is AN2 Therapeutics headquartered?
AN2 Therapeutics is headquartered in Menlo Park, CA.
-
What is the size of AN2 Therapeutics?
AN2 Therapeutics has 21 total employees.
-
What industry is AN2 Therapeutics in?
AN2 Therapeutics’s primary industry is Drug Discovery.
-
Is AN2 Therapeutics a private or public company?
AN2 Therapeutics is a Public company.
-
What is AN2 Therapeutics’s stock symbol?
The ticker symbol for AN2 Therapeutics is ANTX.
-
What is the current stock price of AN2 Therapeutics?
As of 20-Nov-2026 the stock price of AN2 Therapeutics is $5.10.
-
What is the current market cap of AN2 Therapeutics?
The current market capitalization of AN2 Therapeutics is $193M.
-
Who are AN2 Therapeutics’s competitors?
Spero Therapeutics, Ambagon Therapeutics, VLP Therapeutics, RedHill Biopharma, and BITT (Drug Discovery) are some of the 6 competitors of AN2 Therapeutics.
-
What is AN2 Therapeutics’s annual earnings per share (EPS)?
AN2 Therapeutics’s EPS for 12 months was -$0.92.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process